Stay updated with breaking news from பென் அஸ்கிவ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups Perceptive Advisors has $515 million for its second fund investing in biotech startups. Portfolio Manager Chris Garabedian says Perceptive Xontogeny Ventures Fund II is looking to make Series A investments in early-stage companies with assets that can show a path to clinical testing. Shares0
When Chris Garabedian set out early last year to raise money for a second Perceptive Advisors fund focused on early-stage biotech startups, it took just a matter of months to draw interest from investors willing to commit more than $1 billion total. The fund could have closed with that much money, maybe more, said Garabedian, the portfolio manager. But it ended up with a little more than half of that, which he described as “the right size.” ....
Perceptive Advisors, a NYC-based investment management firm focused on the life sciences sector, closed Perceptive Xontogeny Venture Fund II, LP, at $515m, to further its early-stage life sciences platform. PXV Fund II includes existing investors from the inaugural fund, new investors including top-tier asset managers, endowments, foundations, family offices, and notable individual investors, and all of the PXV Fund II Partners. The close of PXV Fund II more than triples assets under management to $725m in less than two years since the closing of the inaugural PXV Fund I, which launched Perceptive’s early-stage venture fund strategy. The PXV Fund strategy complements Perceptive Advisors’ Life Sciences Fund (hedge fund) and Credit Opportunities Funds as it will be solely focused on early-stage venture capital and expects to be the sole or predominant lead investor in Series A financings in the range of $20-40m with capacity to participate in subsequent Series B fi ....
Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Legendary ring announcer Michael Buffer isn’t one to make too many slip-ups in the Boxing ring, but he recently spoke out about a big mistake he made just before the Ben Askren vs. Jake Paul fight. As fight fans watched from around the world, Buffer mispronounced Askren’s name during the fighter introductions, with the longtime announcer saying “Ben Askew” instead of “Ben Askren”. In a way, the moment added to the hilarity of the event; which included unusual commentary by Oscar De La Hoya and Snoop Dogg. Buffer said in a recent interview with TooFab that he regrets making the verbal mistake leading up to the big fight. ....